Frontage Laboratories Brings New GMP Manufacturing Facility Fully Online

Frontage Laboratories, Inc. has completed GMP validation of its new manufacturing facility, opened in May 2025 and validated in October 2025.

The site is now fully operational, supporting Phase III clinical batches, PPQ activities, and small-scale commercial manufacturing.

What the New Facility Supports?

The facility is designed for end-to-end drug development and manufacturing, covering both clinical and commercial needs.

It supports:

• Sterile dosage forms such as vials, syringes, and cartridges
• Non-sterile products including tablets, capsules, ointments, gels, and oral liquids
• High-potency compounds handled in dedicated containment suites

Manufacturing rooms meet ISO GMP classifications, backed by formulation, analytical, and microbiology laboratories.

Key Equipment Investments

Frontage has significantly expanded its manufacturing infrastructure.

New additions include:

• Three automated aseptic filling lines for vials, syringes, and cartridges
• Two new isolators for potent compound handling and aseptic filling
• Gerties roller compactor for dry granulation
• Korsch tablet press for solid oral dosage forms
• Xcelodose system for precise low-dose filling
• Integrated labeling systems and supporting equipment

These upgrades improve efficiency, quality, and speed to market.

Why This Matters for Pharma Companies?

The expanded facility is built to support:

• Faster clinical trial execution
• Streamlined tech transfer to commercial scale
• Reduced timelines for regulatory-ready manufacturing

This is particularly relevant for small and mid-sized pharma companies targeting rapid development or market entry.

Strategic Impact

By combining advanced manufacturing technology with a comprehensive quality system, Frontage strengthens its position as a full-service CRDMO partner.

The focus is clear: fewer handoffs, faster timelines, and reliable GMP execution.

Leadership Perspective

According to Dr. Song Li, Chairman of Frontage, the facility strengthens Frontage’s ability to manage every stage of pharmaceutical development.

The goal is to help customers optimize both cost and quality, while accelerating patient access to medicines.

About Frontage Laboratories

Frontage Laboratories, Inc. is a US-based global CRDMO and a subsidiary of Frontage Holdings Corporation (HKEX: 1521.HK).

With 26 sites worldwide and over 25 years of experience, Frontage supports drug discovery through commercial manufacturing.

Its services span API synthesis, formulation, GMP manufacturing, clinical trials, bioanalysis, and central lab operations.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!